US Patent

US11801237 — Amorphous kinase inhibitor formulations and methods of use thereof

Method of Use · Assigned to Deciphera Pharmaceuticals LLC · Expires 2040-12-30 · 15y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects amorphous compound formulations useful in treating disorders related to the activity of the c-KIT and PDGFRα kinases.

USPTO Abstract

Provided herein is an amorphous compound represented by Formula (I):and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRÎ± kinases, and oncogenic forms thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3219`	—

Patent Metadata

Patent number: US11801237
Jurisdiction: US
Classification: Method of Use
Expires: 2040-12-30
Drug substance claim: No
Drug product claim: Yes
Assignee: Deciphera Pharmaceuticals LLC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.